Triple
T23417456
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Bristol Myers Squibb |
E560549
|
entity |
| Predicate | product |
P490
|
FINISHED |
| Object | Revlimid |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Revlimid | Statement: [Bristol Myers Squibb, product, Revlimid]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Revlimid Context triple: [Bristol Myers Squibb, product, Revlimid]
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
pomalidomide
Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Revlimid Target entity description: Revlimid is a cancer medication (lenalidomide) primarily used to treat multiple myeloma and certain myelodysplastic syndromes.
-
A.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
pomalidomide
Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454cb1108190ab21ada5411a7146 |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1a516d158819081e9710b4e372a21 |
completed | April 29, 2026, 6:28 a.m. |
Created at: April 17, 2026, 5:39 p.m.